Procter & Gamble (PG) Price on Solana

Procter & Gamble agreed to acquire supplements brand Thorne for $3.8 billion as part of a push to grow its health business, a move that reflects a broader structural shift in how consumers allocate spending across beauty, health, and wellness. A survey of 1,000 consumers conducted between May and June found that nearly 100% now treat the three categories as a single budget item, according to AlixPartners research cited by CNBC — a convergence that retailers including Walmart, Ulta Beauty, Target, and Sephora are actively responding to by redesigning store layouts and launching dedicated wellness sections.

The deal positions P&G on the acquisitive side of an industry divide: while 40% of consumers expect traditional beauty companies to expand into health offerings, 42% of executives surveyed prefer staying within their existing categories. Science-backed and dermatologist-endorsed products are gaining share as consumers increasingly research purchases through social media rather than relying on brand messaging. Skincare — which spans all three segments — posted 8% revenue growth in the first half of 2026. The rise of GLP-1 drugs is also reshaping product development priorities across the category.

Procter & Gamble has lagged the broader market significantly over the past year, dropping 7.8% while the Nasdaq gained 21.6% — a gap of nearly 30 percentage points. The stock sits roughly 14% below its 52-week high of $167.25 and has traded below its 200-day moving average since mid-March, though it remains above its 50-day average. Year-to-date the picture is more modest, with PG marginally positive against the Nasdaq's 13.6% rise. Rival Colgate-Palmolive has compounded the narrative, outperforming PG by about 9 percentage points over twelve months.

In August, P&G moved to diversify beyond its core household brands — Tide, Pampers, Gillette, and Crest among them — by acquiring Thorne, a premium wellness company, in a deal the company framed as a meaningful extension of its Personal Health Care segment. Analysts remain constructively positioned on the $343 billion market-cap company: 26 analysts hold a collective Moderate Buy consensus with a mean price target of $160.58, implying roughly 12% upside from current levels.

Procter & Gamble is leaning into marketing-led product innovation to refresh its mature household categories, with Charmin launching the "Forever Roll" alongside a "Roommate Trials" campaign and Swiffer introducing a "Hair Magnet" product developed in collaboration with hair expert Jen Atkin. The moves target everyday pain points in shared living and home cleaning, reinforcing the brand equity P&G depends on to maintain pricing power in competitive consumer staples segments.

Analysts note these launches do not shift the near-term investment thesis — margin protection amid rising input costs and currency headwinds remains the key short-term catalyst to watch. P&G posted $19.6 billion in operating cash flow in fiscal 2026 and marked its 70th consecutive annual dividend increase, with plans to return approximately $15 billion to shareholders via dividends and buybacks in fiscal 2027. Community fair-value estimates for PG range from roughly $108 to $197 per share, with one projection placing fair value at $163.43 based on projected 2029 revenue of $95 billion.

Procter & Gamble's fiscal 2027 guidance is straining investor confidence even as the company pursues its $3.8 billion acquisition of health and wellness brand Thorne. For Q4 fiscal 2026, net sales rose 2% year-over-year to $21.2 billion but organic sales were flat, and core EPS declined 3% to $1.43. Full-year fiscal 2026 net sales grew 3% to $87.0 billion, with organic growth of just 1% driven entirely by price increases rather than volume gains.

Management's fiscal 2027 outlook projects core EPS growth of only 0% to 3%, weighed down by roughly $1 billion in after-tax commodity, energy, and transportation cost headwinds plus $0.56 per share in combined currency and net interest expense drags. The Thorne deal — expected to close in Q4 2026 — is designed to expand P&G into a clinical-credibility wellness segment, leveraging Thorne's 40-year practitioner network and AI wellness advisory tools, but it adds near-term cost pressure on top of an already tight margin environment. P&G returned $10.2 billion to shareholders via dividends and $5.0 billion in buybacks during fiscal 2026, with similar allocations planned for 2027.

Procter & Gamble completed a leadership transition on August 1, 2026, as Jon Moeller retired after 38 years with the company and Shailesh Jejurikar assumed the Chairman role, adding it to his existing responsibilities as President and CEO. Jejurikar has been part of P&G's global leadership group since 2014, with a track record centered on supply chain modernization, IT infrastructure, and global business services — areas the company has leaned on as it pursues AI-driven efficiency initiatives and cost discipline heading into fiscal 2027.

Analysts characterize the move as continuity rather than a strategic reset, noting that operational delivery against near-term targets remains the central investor narrative. P&G has guided for 1–5% EPS growth and 1–3% sales growth in full-year 2027, with roughly $1 billion in headwinds from Iran-related geopolitical costs and a projected 5% earnings decline in Q1. Investors are expected to focus on quarterly execution — category volume recovery and productivity outcomes — rather than the governance structure itself.

Procter & Gamble has agreed to acquire Thorne, a science-driven health supplements brand, for $3.8 billion. CEO Shailesh Jejurikar announced the deal on CNBC's "Squawk on the Street" on August 4, 2026. Thorne was on track to generate approximately $650 million in sales in 2026, and P&G Health Care CEO Paul Gama described the brand as having "built a highly trusted brand at the forefront of personalized health."

Thorne was founded in 1984, went public in 2021 at a $525 million valuation, and was taken private in 2023 for $680 million by L Catterton, the LVMH-backed investment firm. The acquisition adds Thorne to an existing P&G health portfolio that includes Metamucil, Align Probiotic, New Chapter vitamins, Oral-B, and Vicks, deepening the company's position in the personalized wellness and self-care categories. The deal is subject to regulatory approval and is expected to close later in 2026.

Procter & Gamble reported Q4 fiscal 2026 net sales of $21.20 billion, missing the $21.38 billion analyst consensus as organic sales came in flat for the period. Volume across the portfolio was unchanged overall, with declines in three of five business segments — grooming, health care, and baby, feminine and family care — partly offset by 3% volume growth in beauty. The result highlights the limits of the pricing-led strategy P&G leaned on through 2023 and 2024: with price increases largely exhausted, lower-income consumers have responded by trading down or stretching products further, and volume has yet to fill the gap. Operating margins contracted for a third consecutive quarter as commodity costs climbed and the company raised marketing spend to defend shelf share, pushing SG&A higher as a share of sales.

P&G issued cautious fiscal 2027 guidance of 1–3% net sales growth and core EPS of $6.89–$7.11, a midpoint below the $7.04 analyst estimate. CFO Andre Schulten attributed much of the uncertainty to Middle East geopolitical tensions and elevated oil-linked input costs, which the company expects to weigh on profit by roughly $1 billion. Core EPS for the quarter came in at $1.43, marginally ahead of the $1.41 estimate but down 3% year over year, while diluted EPS fell 15% to $1.26 and net earnings declined 16% to $3.04 billion.

Procter & Gamble's board declared a quarterly dividend of $1.0885 per share on common and ESOP convertible preferred stock, with a record date of July 24, 2026 — continuing its decades-long streak of consistent payouts. With the stock trading around $147.41, the dividend announcement has drawn fresh attention to PG's valuation ahead of its next earnings report.

Analysis highlights a notable split between valuation methods: a narrative-based model puts fair value at $122.36, implying the stock is roughly 20% overvalued at current prices, while a discounted cash flow model arrives at $191.89, suggesting approximately 23% upside. The disconnect reflects PG's dual identity as a premium stability play — investors pay for predictability and dividend reliability, even as year-over-year total shareholder returns remain slightly negative at -4.1%.

Procter & Gamble declared a quarterly dividend of US$1.0885 per share on its common stock and ESOP preferred shares, payable on or after August 17, 2026 to shareholders of record as of July 24, 2026. The increase extends P&G's seven-decade pattern of annual dividend growth, underscoring management's commitment to returning cash to shareholders even as the company navigates tariff-related cost headwinds and uneven consumer demand.

The dividend hike comes alongside a previously announced restructuring that will trim up to 7,000 non-manufacturing roles, with management framing the dual moves as complementary: cost savings from workforce reductions are intended to fund ongoing productivity improvements and sustain the dividend program. Simply Wall St estimates P&G's fair value at approximately $163, implying roughly 9% upside from recent trading levels, though community estimates span a wide range from $121 to $192 per share.

Procter & Gamble plans to eliminate up to 7,000 non-manufacturing roles by fiscal year 2027 as the consumer goods giant looks to absorb rising costs from trade tariffs. The cuts target office and support positions — leaving factory and production jobs untouched — and reflect a deliberate pivot toward cost productivity rather than relying solely on price increases to defend margins under tariff pressure.

The restructuring would free up resources P&G could redeploy toward marketing investment, product development, and AI-powered supply chain tools. With peers including Unilever, Colgate-Palmolive, and Kimberly-Clark facing the same tariff environment, P&G's move signals that structural headcount reduction, not just pricing power, is becoming a primary competitive lever across consumer staples.